We have developed multiplex proteomic tests to guide therapeutic decision making in rheumatoid arthritis (RA). Through proteomic discovery, we have identified autoantibody and cytokine profiles with predictive utility for two actionable situations in RA. First, to facilitate early diagnosis and initiation of disease-modifying therapies that alter the natural history of RA. Second, to identify patients likely to respond to anti-TNF therapeutics.
Flow Chemistry